Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 7/20 | 0.42 |
| ▸ | BMP1 | P13497 | 3/20 | 0.41 |
| ▸ | MMP8 | P22894 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324238 | 1.00 | AVPR1B (0.42) | AVPR1BBMP1MMP8F2AVPR1A | |
| SCHEMBL6323789 | 0.93 | F2 (0.42) | AVPR1BBMP1MMP8F2AVPR1A | |
| SCHEMBL6323795 | 0.93 | F2 (0.42) | AVPR1BBMP1MMP8F2AVPR1A | |
| SCHEMBL6324767 | 0.89 | BMP1 (0.40) | AVPR1BBMP1MMP8F2AVPR1A | |
| SCHEMBL6324764 | 0.89 | BMP1 (0.40) | AVPR1BBMP1MMP8F2AVPR1A | |
| SCHEMBL6318024 | 0.87 | BMP1 (0.43) | AVPR1BBMP1MMP8F2AVPR1A | |
| SCHEMBL6319300 | 0.81 | F2 (0.47) | AVPR1BBMP1MMP8F2AVPR1A | |
| SCHEMBL6317436 | 0.81 | F2 (0.47) | AVPR1BBMP1MMP8F2AVPR1A | |
| SCHEMBL6318097 | 0.81 | F2 (0.49) | AVPR1BBMP1MMP8F2AVPR1A | |
| SCHEMBL6318099 | 0.81 | F2 (0.49) | AVPR1BBMP1MMP8F2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | claimed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | claimed |
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | disclosed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | HAVCR2, ZC3HAV1, MAVS | AVPR1B 2300/4885BMP1 3222/4885MMP8 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.